With a new oncology head, Takeda revamps its R&D strategy

[cafead]

via As former chief medical officer for CRISPR Therapeutics, Dr. PK Morrow spent the end of 2023 helping to usher in the first-ever FDA approval for a CRISPR-based treatment. But that wasn’t the only FDA approval on her radar. She was also tracking the status of Takeda Pharmaceuticals’ metastatic colorectal cancer treatment Fruzaqla, the first novel, chemotherapy-free treatment option regardless of biomarker status to win U.S. approval in more than a decade.

article source